Aromatase inhibitors for breast cancer

Rev Endocr Metab Disord. 2007 Sep;8(3):215-28. doi: 10.1007/s11154-007-9039-z.


Endocrine therapy is a mainstay for the many women who develop in situ or invasive steroid receptor-positive breast cancer. The use of tamoxifen has reduced mortality in such women. Recently estrogen deprivation strategies have come under scrutiny. Here the use of aromatase inhibitors for treatment of postmenopausal endocrine-responsive breast cancer in the metastatic, adjuvant, and preoperative settings is reviewed.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use
  • Aromatase Inhibitors / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / physiopathology
  • Drug Therapy, Combination
  • Female
  • Humans
  • Postmenopause / physiology
  • Tamoxifen / therapeutic use


  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Tamoxifen